Jessica Korpacz

News

New Data on Biologic Treatment Safety in Solid-Organ Transplant Recipients

09/16/2021

A recent systematic review of the safety of biologics for the treatment of autoimmune/inflammatory diseases in recipients of solid-organ transplants found that no therapeutic or demographic factors were associated with the occurrence of...

A recent systematic review of...

09/16/2021

The Dermatologist

News

LED Therapy Provides Promising Results for Treating Eyebrow Loss in Frontal Fibrosing Alopecia

09/17/2021

Jessica Korpacz ;

Light-emitting diode therapy increased the number of hairs and their thickness after 10 irradiations and the hair remained that way when measured again 6 months later at a follow-up visit.

Light-emitting diode therapy...

09/17/2021

The Dermatologist

News

Post Hoc Analysis Details Key Adverse Events in Patients With Advanced BCC Being Treated by Sonidegib or Vismodegib

09/17/2021

Jessica Korpacz ;

Researchers compared the main adverse events of treatments for advanced basal cell carcinoma, finding sonidegib is tolerated better by more patients because of the lower overall incidence rate and a slower, less severe onset of certain AEs.

Researchers compared the main...

09/17/2021

The Dermatologist

News

Two Phase 3 Trials Show Tofacitinib Effectively Treats PsA Regardless of Methotrexate Background Dose

09/17/2021

Jessica Korpacz ;

Analysis revealed that the efficacy of tofacitinib was greater than the placebo after 3 months of treating PsaA regardless of background doses of methotrexate.

Analysis revealed that the...

09/17/2021

The Dermatologist

News

COVID-19 Risk Comparison in Patients With IMIDs vs Matched Non-IMIDs from the General Population

09/17/2021

Jessica Korpacz ;

A population-based study found that patients across all IMIDs were more likely to be tested for SARS-CoV-2, though this group tested positive for SARS-CoV-2 at the same rate as those without IMIDs.

A population-based study found...

09/17/2021

The Dermatologist

News

Secukinumab Shows 2-Year Sustained Improvement for Patients Experiencing Concomitant Nail Psoriasis

09/17/2021

Jessica Korpacz ;

The FUTURE 5 study revealed that secukinumab can improve nail disease as well as signs and symptoms of PsA and a low rate of radiographic progression for 2 years in patients who experience PsA with noncomitant nail psoriasis.

The FUTURE 5 study revealed that...

09/17/2021

The Dermatologist

News

High Body Surface Area of Severe Psoriasis Linked to Increased Risk of Developing PsA

09/17/2021

Jessica Korpacz ;

Body surface area of patients with severe psoriasis was assessed to be a strong predictor of developing psoriatic arthritis with obesity and depression being additive risk factors.

Body surface area of patients...

09/17/2021

The Dermatologist

Feature Story

The Basics of Conducting Clinical Trials

12/08/2021

Jessica Korpacz ;

Lauren Mateja ;

Clinical trials offer advantages to both physicians and their patients, from a business investment to access to novel therapeutics for various diseases.

Clinical trials offer advantages...

12/08/2021

The Dermatologist